Lilly’s Kisunla Approved to Treat Early Symptomatic Alzheimer's Disease In July, the FDA cleared Eli Lilly’s Kisunla (donanemab-azbt), an...

Dementia and Alzheimer’s are diseases scientists, doctors, and patients struggle with on a daily basis. A new study shows that a combined blood...

Biopharma stock Alpha Cognition (CSE:ACOG) receives FDA approval for Zunveyl, its treatment for mild-to-moderate Alzheimer's disease.

Deep sleep is essential for consolidating memories. People with mild cognitive impairment, an early sign of Alzheimer’s disease, often experience...

TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen...

The European Medicines Agency has rejected the Alzheimer’s drug Leqembi – a major setback for developers Eisai and Biogen. ...

A study into Alzheimer's disease, completed by researchers in the BRC's Dementia Theme, has found that data gathered from online cognition testing...

Half of Alzheimer’s disease cases are preventable. To do this, you need to minimize the impact of 14 risk factors, according to reports Daily...

Extracts from 11 species, belonging to eight genera of seaweed, could effectively help the treatment of Alzheimer's patients suffering from cognitive...

Alzheimer's disease incidence is increasing, with early-onset dementia being more common than previously reported.